Literature DB >> 19850311

Prime-boost immunization with HA/C3d DNA followed by a recombinant pseudorabies virus boost enhanced protective immunity against H3N2 swine influenza virus in mice.

Guo-Xin Li1, Yan-Jun Zhou, Hai Yu, Zhi-Jun Tian, Li-Ping Yan, Qiang Zhang, Shou-Ping Hu, Guang-Zhi Tong.   

Abstract

DNA and recombinant virus vaccines against swine influenza virus (SIV) have been pursued with promising results, but induce poor immunogenicity. This study evaluated the effects of a vaccine regimen in mice including priming with three DNA vaccines expressing soluble HA (sHA), complete HA (tmHA), or sHA fused with three copies murine C3d (sHA-mC3d3) and boosting with recombinant pseudorabies virus expressing HA (rPRV-HA). Immune responses were monitored by ELISA, HI assays, and virus neutralization. Protective efficacy was evaluated by virus isolation from lungs, distribution in tissues, and pathology following challenge with H3N2 SIV. Priming with sHA-mC3d3 and boosting with rPRV-HA induced higher levels of HA-specific antibodies and yielded the most effective protection. This finding implied that priming with a DNA vaccine expressing C3d fused with antigen and boosting with a recombinant vector vaccine is an effective way to induce protective humoral immunity and prevent some infectious diseases. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19850311     DOI: 10.1016/j.rvsc.2009.09.005

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  2 in total

Review 1.  Epidemic status of Swine influenza virus in china.

Authors:  Weili Kong; Jiahui Ye; Shangsong Guan; Jinhua Liu; Juan Pu
Journal:  Indian J Microbiol       Date:  2013-07-16       Impact factor: 2.461

2.  AIV polyantigen epitope expressed by recombinant baculovirus induces a systemic immune response in chicken and mouse models.

Authors:  Lei Yu; Jun Pan; Guangli Cao; Mengsheng Jiang; Yunshan Zhang; Min Zhu; Zi Liang; Xing Zhang; Xiaolong Hu; Renyu Xue; Chengliang Gong
Journal:  Virol J       Date:  2020-08-05       Impact factor: 4.099

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.